Jakafi Coupons & Discount Card - Compare Prices Near You

Here are essential safety and warning details for Jakafi (ruxolitinib) that you should carefully consider. Consult your healthcare provider for advice tailored to your situation.

• Low Blood Cell Counts: The use of Jakafi can lead to a decrease in red and white blood cells, as well as platelets. A reduction in red blood cells may cause fatigue, while a lower count of white blood cells can increase the risk of infections. A decreased platelet count may result in difficulty stopping bleeding.

• Increased Infection Risk: Patients taking Jakafi have a higher susceptibility to bacterial, fungal, and viral infections. Serious conditions like tuberculosis (TB) may arise, especially in those with a history of TB, herpes simplex infection, or who have traveled to areas with high TB prevalence.

• Effects When Discontinuing Jakafi: Stopping Jakafi treatment, particularly for myelofibrosis or polycythemia vera, might lead to the recurrence of previous symptoms and could cause fever, breathing difficulties, low blood pressure, or serious conditions like disseminated intravascular coagulation (DIC) and organ failure.

• Skin Cancer Risk: There is a possibility of developing new skin cancers, such as basal cell carcinoma, squamous cell carcinoma, or Merkel cell carcinoma. Regular skin examinations are advised, and any unusual skin changes should be reported to an oncologist or dermatologist promptly.

• Potential Heart Problems and Stroke: Although Jakafi is not approved for rheumatoid arthritis, similar JAK inhibitors have been linked to serious heart issues and strokes, particularly in patients with existing risk factors or those who are current or former smokers.

• Blood Clot Risk: Similar JAK inhibitors used for rheumatoid arthritis have been associated with blood clots like deep vein thrombosis (DVT) and pulmonary embolism (PE). Jakafi is not approved for rheumatoid arthritis treatment.

• New Cancer Risk: There is a potential risk for new cancers, such as lymphoma, especially in current or past smokers, based on observations from other JAK inhibitors used for rheumatoid arthritis. Discuss any concerns with your oncology or hematology specialist.

Please note that there are no specific contraindications listed for Jakafi. Always seek personalized medical advice from your healthcare provider.

When taking this medication, you may encounter some common side effects that are generally mild and manageable. These include dizziness, diarrhea, headache, gas, weight gain, and muscle, bone, or joint pain. Some individuals might also experience infections like urinary tract or viral infections, anemia, low white blood cells, low platelets, and increased cholesterol or liver enzyme levels. If these effects persist or worsen, it's advisable to consult your healthcare provider to ensure proper management.

More serious side effects, although rare, demand urgent medical attention. These include symptoms of low white blood cells and infections, such as fever, chills, severe tiredness, body aches, or trouble breathing. Low platelet levels can lead to unexpected bleeding or bruising, nosebleeds, and blood in urine or stool. Serious heart issues, strokes, and blood clots are critical side effects to be aware of. These can manifest as chest pain, chest tightness, sudden numbness or weakness on one side of the body, severe headaches, difficulty breathing, speaking, or walking, and swelling in the limbs. Immediate medical care is crucial if any of these severe symptoms are observed.

Additionally, there is a very rare but significant risk of a brain infection called progressive multifocal leukoencephalopathy (PML), which may present as confusion, difficulty concentrating, seizures, or vision changes. A serious allergic reaction, though uncommon, can also occur, indicated by a rash, severe dizziness, trouble breathing, or swelling of the face, tongue, or throat. If any unusual symptoms arise, contacting your healthcare provider promptly is important to ensure safety and well-being.